{"content":"<li class=\"n-box-item date-title\" data-end=\"1482209999\" data-start=\"1482123600\" data-txt=\"Sunday, December 22, 2019\">Monday, December 19, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3231555\" data-ts=\"1482186470\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231555-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After-hours Gainers / Losers</a></h4><ul><li><b>Top gainers, as of 5:15 p.m.:</b> <a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a> <font color='green'>+157.7%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+8.1%</font>. <a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='green'>+6.1%</font>. <a href='https://seekingalpha.com/symbol/CMS' title='CMS Energy Corporation'>CMS</a>&nbsp;<font color='green'>+4.9%</font>. <a href='https://seekingalpha.com/symbol/KLAC' title='KLA-Tencor Corporation'>KLAC</a>&nbsp;<font color='green'>+2.4%</font>.</li><li><b><b>Top losers</b><b>, as of 5:15 p.m.</b>:</b> <a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a> <font color='red'>-7.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231555\" data-linked=\"After-hours Gainers / Losers\" data-tweet=\"$CNAT $RGLS $AUPH - After-hours Gainers / Losers https://seekingalpha.com/news/3231555-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3231555-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231554\" data-ts=\"1482186082\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/S\" target=\"_blank\">S</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231554-claure-sprint-definitely-moving-in-right-direction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Claure: Sprint &#39;definitely moving in right direction&#39;</a></h4><ul>   <li>\"We're definitely moving in the right direction,\" says Sprint (<a href=\"https://seekingalpha.com/symbol/S\" title=\"Sprint Corporation\">S</a> <font color=\"green\">+2.4%</font>) chief Marcelo Claure about heading toward the midpoint of a five-year turnaround plan. \"We <a href=\"http://www.bizjournals.com/kansascity/news/2016/12/19/claure-sprint-rally-startup-mentality.html\" target=\"_blank\">run it like a big start-up</a>.\"</li>    <li>Claure spent Saturday on the sales floor of one of the company's newest locations, working to prove he's \"still got it when it comes to sales.\"</li>    <li>\u201cIt\u2019s very quick decision making, no bureaucracy, try new things, don\u2019t be scared to fail and dream big,\u201d he tells the <i>Kansas City Business Journal.</i> \u201cAll the basics that you apply to entrepreneurs and a start-up, we apply to the Sprint re-startup.\u201d</li>    <li>The biggest milestones the company's hit so far? Slashing costs by $4B, getting back to positive operating income and free cash flow, and surpassing rivals AT&amp;T and Verizon in net adds.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231554\" data-linked=\"Claure: Sprint &#39;definitely moving in right direction&#39;\" data-tweet=\"$S - Claure: Sprint &#39;definitely moving in right direction&#39; https://seekingalpha.com/news/3231554-claure-sprint-definitely-moving-in-right-direction?source=tweet\" data-url=\"https://seekingalpha.com/news/3231554-claure-sprint-definitely-moving-in-right-direction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231545\" data-ts=\"1482183565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REN\" target=\"_blank\">REN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231545-resolute-energy-to-launch-3_8m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Resolute Energy to launch 3.8M-share offering</a></h4><ul>\n<li>Resolute Energy (NYSE:<a href=\"https://seekingalpha.com/symbol/REN\" title=\"Resolute Energy Corporation\">REN</a>) <font color=\"red\">-5.6%</font> AH after announcing a public offering of 3.8M common shares, with an underwriters option to purchase up to an additional 570K shares.</li>\n<li>REN says it plans to use the proceeds to repay its second lien secured term loan, with any  additional proceeds to partially repay outstanding debt under its revolving credit facility.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231545\" data-linked=\"Resolute Energy to launch 3.8M-share offering\" data-tweet=\"$REN - Resolute Energy to launch 3.8M-share offering https://seekingalpha.com/news/3231545-resolute-energy-to-launch-3_8m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3231545-resolute-energy-to-launch-3_8m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231544\" data-ts=\"1482183281\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NPTN\" target=\"_blank\">NPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231544-neophotonicsminus-20-offloads-low-speed-unit-decreases-q4-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeoPhotonics -20%; offloads low-speed unit, decreases Q4 guidance</a></h4><ul>\n<li>Through a transaction valued at $26.4M, NeoPhotonics (NYSE:<a href=\"https://seekingalpha.com/symbol/NPTN\" title=\"NeoPhotonics Corporation\">NPTN</a>) agrees to sell its access and low-speed transceiver business (intellectual property, inventory, fixed assets for PON products including GPON and GEPON transceivers at up to 10G data rates, and 10G and below telecom, bidirectional and speciality transceiver products) to APAT Optoelectronics Components of Shenzhen, China.</li>\n<li>Updating prior Q4 outlook given high-speed product demand that's exceeding supply capacity, lower-than-expected production yields and resulting shipment delays and higher manufacturing costs, NeoPhotonics now projects Q4 at $105M-$109M in revenue (vs. $109M-$115M guided November 3), 28%-31% gross margins (vs. 30%-33%), $27M-$29M (vs. $26M-$28M) in operating expenses, and $0.03-$0.11 in EPS (vs. $0.13-$0.21).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231544\" data-linked=\"NeoPhotonics -20%; offloads low-speed unit, decreases Q4 guidance\" data-tweet=\"$NPTN - NeoPhotonics -20%; offloads low-speed unit, decreases Q4 guidance https://seekingalpha.com/news/3231544-neophotonicsminus-20-offloads-low-speed-unit-decreases-q4-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3231544-neophotonicsminus-20-offloads-low-speed-unit-decreases-q4-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231534\" data-ts=\"1482182100\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231534-commercial-chief-set-to-get-top-nod-biogen-shares-ease-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Commercial chief set to get top nod at Biogen; shares ease 1% after hours</a></h4><ul>\n<li>Biogen (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BIIB\" title=\"Biogen Inc.\">BIIB</a>) is reportedly about to <a href=\"http://www.reuters.com/article/us-biogen-ceo-idUSKBN1482CR\" target=\"_blank\">announce </a>that chief commercial officer Michel Vounatsos will be its next CEO according to Reuters. Mr. Vounatsos is a newcomer to the company, joining the firm in March after a 20-year career at Merck.</li>\n<li>Shares slip <font color=\"red\">1%</font> after hours on increased volume.</li>\n<li>\n<strong>Update</strong>: In a statement, Biogen names Mr. Vounatsos as CEO effective January 6, 2017.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231534\" data-linked=\"Commercial chief set to get top nod at Biogen; shares ease 1% after hours\" data-tweet=\"$BIIB - Commercial chief set to get top nod at Biogen; shares ease 1% after hours https://seekingalpha.com/news/3231534-commercial-chief-set-to-get-top-nod-biogen-shares-ease-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3231534-commercial-chief-set-to-get-top-nod-biogen-shares-ease-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231507\" data-ts=\"1482180871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231507-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+59%</font>. <a href='https://seekingalpha.com/symbol/STRP' title='Straight Path Communications Inc.'>STRP</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/UIS' title='Unisys Corporation'>UIS</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SMSI' title='Smith Micro Software, Inc.'>SMSI</a> <font color='red'>-8%</font>. IMN <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='red'>-7%</font>. COOL <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231507\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$GSAT $XGTI-OLD $STRP - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3231507-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3231507-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231522\" data-ts=\"1482180809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231522-interpace-diagnostics-sells-2m-shares-of-common-stock-0_53-shares-down-29\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace Diagnostics sells 2M shares of common stock at $0.53; shares down 29%</a></h4><ul>\n<li>Nano cap Interpace Diagnostics (<a href=\"https://seekingalpha.com/symbol/IDXG\" title=\"Interpace Diagnostics Group, Inc.\">IDXG</a> <font color=\"red\">-28.8%</font>) slumps on double normal volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1054102/000143774916043513/ex99-1.htm\" target=\"_blank\">announcement </a>of a direct placement of 2M shares of common stock at $0.53 and pre-funded warrants to purchase 1.6M shares of common at $0.52 to a single institutional investor.</li>\n<li>Gross proceeds will be $1.89M. Closing date is December 22.</li>\n<li>Friday's close was $1.11.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231522\" data-linked=\"Interpace Diagnostics sells 2M shares of common stock at $0.53; shares down 29%\" data-tweet=\"$IDXG - Interpace Diagnostics sells 2M shares of common stock at $0.53; shares down 29% https://seekingalpha.com/news/3231522-interpace-diagnostics-sells-2m-shares-of-common-stock-0_53-shares-down-29?source=tweet\" data-url=\"https://seekingalpha.com/news/3231522-interpace-diagnostics-sells-2m-shares-of-common-stock-0_53-shares-down-29\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231520\" data-ts=\"1482180401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDI\" target=\"_blank\">RDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231520-lawndale-capital-weighs-in-on-new-reading-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lawndale Capital weighs in on new Reading offer</a></h4><ul>     <li>Lawndale Capital Management's analysis on the new Reading International (<a href=\"https://seekingalpha.com/symbol/RDI\" title=\"Reading International, Inc.\">RDI</a> <font color=\"green\">+4.3%</font>) offer from a Patton-led consortium is that it undervalues the company.</li>\n<li>Applying an EV/EBITDA valuation methodology on Reading's real estate development segment doesn't properly value the company's undeveloped parcels in the U.S., Australia and New Zealand, <a href=\"https://seekingalpha.com/author/andrew-shapiro/articles#regular_articles\" target=\"_blank\">Lawndale's Andrew Shapiro</a> tells Seeking Alpha.</li>\n<li>Shapiro thinks the board should appoint a special committee of directors independent of the Cotter family and retain bankers to advise on alternatives to the \"underpriced\" bid.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231498-reading-international-pops-new-buyout-offer-hand\" target=\"_blank\">Reading International pops with new buyout offer in hand</a> (Dec. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231520\" data-linked=\"Lawndale Capital weighs in on new Reading offer\" data-tweet=\"$RDI - Lawndale Capital weighs in on new Reading offer https://seekingalpha.com/news/3231520-lawndale-capital-weighs-in-on-new-reading-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3231520-lawndale-capital-weighs-in-on-new-reading-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231515\" data-ts=\"1482179406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231515-analysts-weigh-in-on-clovis-rucaparib-approval-in-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts weigh in on Clovis&#39; rucaparib approval in U.S.</a></h4><ul>\n<li>Clovis Oncology (<a href=\"https://seekingalpha.com/symbol/CLVS\" title=\"Clovis Oncology\">CLVS</a> <font color=\"green\">+10.6%</font>) has given up some of its gain from today's FDA approval of Rubraca (rucaparib) for the treatment of ovarian cancer. Shares are currently exchanging hands at ~$41.20, down 11.5% from the intraday high of $46.97.</li>\n<li>Guggenheim's Tony Butler says Tesaro is seeking a broader label for niraparib and adds that rucaparib more closely resembles AstraZeneca's (<a href=\"https://seekingalpha.com/symbol/AZN\" title=\"AstraZeneca Group plc\">AZN</a> <font color=\"red\">-3.3%</font>) <a href=\"https://www.lynparza.com/\" target=\"_blank\">Lynparza </a>(olaparib).</li>\n<li>Janney's Debjit Chattopadhyay rates Clovis neutral citing the encroachment of multiple PARPs as maintenance therapy into third-line treatments.</li>\n<li>Piper's Steven Breazzano agrees that maintenance use is a key and echos Janney's neutral stance.</li>\n<li>Stifel's Thomas Shrader rates the stock a buy because he sees Rubraca overtaking Lynparza and coalescing with comparable market share to niraparib.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231515\" data-linked=\"Analysts weigh in on Clovis&#39; rucaparib approval in U.S.\" data-tweet=\"$CLVS $CLVS $AZN - Analysts weigh in on Clovis&#39; rucaparib approval in U.S. https://seekingalpha.com/news/3231515-analysts-weigh-in-on-clovis-rucaparib-approval-in-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3231515-analysts-weigh-in-on-clovis-rucaparib-approval-in-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231509\" data-ts=\"1482177480\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231509-films-struggle-to-find-box-office-footing-against-rogue-one\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Other films struggle to find box office footing against &#39;Rogue One&#39;</a></h4><ul>   <li>Aside from a <a href=\"https://seekingalpha.com/news/3231504-disney-six-month-highs-merrill-adds-stock-us-1-list\" target=\"_blank\"><i>Star Wars</i>-dominated weekend</a>, other box-office contenders struggled to find scraps.</li>    <li>\n<i>Collateral Beauty</i> (<a href=\"https://seekingalpha.com/symbol/TWX\" title=\"Time Warner Inc.\">TWX</a> <font color=\"green\">+0.3%</font>), the only major contender that didn't clear the weekend for Disney's (<a href=\"https://seekingalpha.com/symbol/DIS\" title=\"The Walt Disney Company\">DIS</a> <font color=\"green\">+1.6%</font>) <i>Rogue One: A Star Wars Story,</i> ambled to $7M and only fourth place, behind holdovers <i>Moana</i> (NYSE:<a href=\"https://seekingalpha.com/symbol/DIS\" title=\"The Walt Disney Company\">DIS</a>), which grossed $11.7M, and <i>Office Christmas Party</i> (<a href=\"https://seekingalpha.com/symbol/VIA\" title=\"Viacom Inc.\">VIA</a> <font color=\"red\">-2.9%</font>, <a href=\"https://seekingalpha.com/symbol/VIAB\" title=\"Viacom Inc.\">VIAB</a> <font color=\"red\">-2%</font>), which drew $8.5M.</li>    <li>The $7M marks the worst wide opening for a movie led by Will Smith. Warner can look to a silver lining in <i>Fantastic Beasts and Where to Find Them,</i> which took $5M for fifth place but a domestic cumulative total of $207.7M.</li>    <li>Among award aspirants in limited release, musical <i>La La Land</i> (<a href=\"https://seekingalpha.com/symbol/LGF.A\" title=\"Lions Gate Entertainment Corp.\">LGF.A</a> <font color=\"green\">+0.6%</font>, <a href=\"https://seekingalpha.com/symbol/SNE\" title=\"Sony Corporation\">SNE</a> <font color=\"green\">+1.2%</font>) cracked the top 10 with $4M despite only playing in 200 theaters, an average of more than $20,000 per. <i>Jackie</i> (<a href=\"https://seekingalpha.com/symbol/FOX\" title=\"Twenty-First Century Fox, Inc.\">FOX</a> <font color=\"red\">-0.3%</font>, <a href=\"https://seekingalpha.com/symbol/FOXA\" title=\"Twenty-First Century Fox, Inc.\">FOXA</a> <font color=\"green\">+0.4%</font>) grossed $550,000 in 84 theaters, averaging about $6,500.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231509\" data-linked=\"Other films struggle to find box office footing against &#39;Rogue One&#39;\" data-tweet=\"$DIS $DIS $VIA - Other films struggle to find box office footing against &#39;Rogue One&#39; https://seekingalpha.com/news/3231509-films-struggle-to-find-box-office-footing-against-rogue-one?source=tweet\" data-url=\"https://seekingalpha.com/news/3231509-films-struggle-to-find-box-office-footing-against-rogue-one\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231504\" data-ts=\"1482176578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231504-disney-to-six-month-highs-merrill-adds-stock-to-us-1-list\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney to six-month highs; Merrill adds stock to US 1 list</a></h4><ul>   <li>Walt Disney (NYSE:<a href=\"https://seekingalpha.com/symbol/DIS\" title=\"The Walt Disney Company\">DIS</a>) is still flying high after the success of its <i>Star Wars</i> spin-off <i>Rogue One,</i> <font color=\"green\">up 1.9%</font> and touching highs it hasn't seen since May.</li>    <li>Merrill Lynch has reiterated its Buy rating and added the stock to its US 1 list, with a $125 price target (implying 18% upside ahead). Going into the weekend, Loop Capital reiterated its Buy rating and $113 price target vs. today's price of $105.92, and Piper Jaffray set a price target of $115.</li>    <li>\n<i>Rogue One</i> <a href=\"https://seekingalpha.com/news/3231281-rogue-one-hauls-big-155m-opening-weekend\" target=\"_blank\">drew $155M</a> domestically and $135.5M overseas, with another bump expected after the New Year when it opens in China.</li>    <li>And while bulls' eyes are on <i>Star Wars</i> today, RBC's Steven Cahall is still <a href=\"https://www.bloomberg.com/news/articles/2016-12-19/espn-s-losing-streak-media-megadeals-put-disney-on-the-hot-seat\" target=\"_blank\">fretting ESPN</a> -- headed for a second year of falling profit and the leading cause of Disney stock's worst annual result in years. He's pushing for divestment of the sports network, joining company with observers like cable titan John Malone.</li>    <li>Even counting the <i>Rogue One</i> rally, DIS is <font color=\"green\">up less than 1%</font> in 2016.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231504\" data-linked=\"Disney to six-month highs; Merrill adds stock to US 1 list\" data-tweet=\"$DIS - Disney to six-month highs; Merrill adds stock to US 1 list https://seekingalpha.com/news/3231504-disney-to-six-month-highs-merrill-adds-stock-to-us-1-list?source=tweet\" data-url=\"https://seekingalpha.com/news/3231504-disney-to-six-month-highs-merrill-adds-stock-to-us-1-list\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231502\" data-ts=\"1482176220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231502-vale-opens-worlds-largest-iron-ore-mine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vale opens world&#39;s largest iron ore mine</a></h4><ul>     <li>Vale (<a href=\"https://seekingalpha.com/symbol/VALE\" title=\"Vale S.A.\">VALE</a> <font color=\"red\">-4.7%</font>) this weekend <a href=\"http://www.reuters.com/article/us-vale-s11d-idUSKBN1460RG\" target=\"_blank\">opened the S11D iron ore mine in Brazil</a> - its biggest project ever, adding 75M metric tons of production when it reaches peak output in four years and firmly lifting Vale over Rio Tinto as the world's top iron ore producer.</li>     <li>Vale invested $14.3B in the mine and processing facilities, along with the expansion of a rail line that will carry ore ~620 miles to a new port terminal for loading onto the world's largest iron ore ships.</li>     <li>S11D will offer some of the best quality ore and lowest costs in the industry, able to produce 90M metric tons/year at full capacity a cost of ~$7/ton, or <a href=\"https://www.bloomberg.com/news/articles/2016-12-17/world-s-largest-iron-ore-mine-becomes-brazil-turnaround-symbol\" target=\"_blank\">41% less than Vale\u2019s current average expense</a>; the mine has a life expectancy of 30 years.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3231502\" data-linked=\"Vale opens world&#39;s largest iron ore mine\" data-tweet=\"$VALE - Vale opens world&#39;s largest iron ore mine https://seekingalpha.com/news/3231502-vale-opens-worlds-largest-iron-ore-mine?source=tweet\" data-url=\"https://seekingalpha.com/news/3231502-vale-opens-worlds-largest-iron-ore-mine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231499\" data-ts=\"1482174032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLBL\" target=\"_blank\">GLBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231499-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GLBL' title='TerraForm Global'>GLBL</a> <font color='green'>+11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231499\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$GLBL - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3231499-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3231499-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231498\" data-ts=\"1482174001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDI\" target=\"_blank\">RDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231498-reading-international-pops-new-buyout-offer-in-hand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reading International pops with new buyout offer in hand</a></h4><ul> <li>Patton Vision issues a letter to shareholders at Reading International (<a href=\"https://seekingalpha.com/symbol/RDI\" title=\"Reading International, Inc.\">RDI</a> <font color=\"green\">+4.6%</font>) informing them that the consortium led by the firm is raising its buyout offer to $18.50 per share.</li>\n<li>On negotiations: \"Our consortium remains confident that there is a foundation for proper engagement between us and the Board of Directors of Reading International, Inc.\"</li> <li>On valuation: \"Our offer represents a 14.8x Enterprise Value / Trailing 12 months EBITDA multiple, whereas AMC's latest offer for Carmike Cinemas represents a 9.2x Enterprise Value / Trailing 12 months EBITDA multiple.\"</li>\n<li>Shares of RDI are <font color=\"green\">up 4.61%</font> to $16.79 and hit a 52-week high of $16.90 earlier.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3231498\" data-linked=\"Reading International pops with new buyout offer in hand\" data-tweet=\"$RDI - Reading International pops with new buyout offer in hand https://seekingalpha.com/news/3231498-reading-international-pops-new-buyout-offer-in-hand?source=tweet\" data-url=\"https://seekingalpha.com/news/3231498-reading-international-pops-new-buyout-offer-in-hand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231489\" data-ts=\"1482172359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TURN\" target=\"_blank\">TURN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231489-harris-harrisplus-3_5-deleverages\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harris &amp; Harris +3.5% as it deleverages</a></h4><ul>\n<li>Harris &amp; Harris (TINY <font color=\"green\">+3.5%</font>) has a balance sheet free of any debt after paying off its credit facility with ORIX Corporate Capital.</li>\n<li>Funds for the payment came from the sale (at a gain) of an investment this quarter.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231489\" data-linked=\"Harris &amp; Harris +3.5% as it deleverages\" data-tweet=\"$TURN - Harris &amp; Harris +3.5% as it deleverages https://seekingalpha.com/news/3231489-harris-harrisplus-3_5-deleverages?source=tweet\" data-url=\"https://seekingalpha.com/news/3231489-harris-harrisplus-3_5-deleverages\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231488\" data-ts=\"1482172357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRWD\" target=\"_blank\">IRWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231488-ironwoods-linzess-okd-in-japan-to-treat-ibs-c-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ironwood&#39;s Linzess OK&#39;d in Japan to treat IBS-C; shares up 3%</a></h4><ul>\n<li>Ironwood Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/IRWD\" title=\"Ironwood Pharmaceuticals, Inc.\">IRWD</a> <font color=\"green\">+2.9%</font>) announces that the Japanese Ministry of Health, Labor and Welfare has approved LINZESS (linaclotide) for the treatment of adults with irritable bowel syndrome. The approval triggers a $15M milestone payment from commercialization partner Astellas Pharma (<a href=\"https://seekingalpha.com/symbol/ALPMF\" title=\"Astellas Pharma, Inc.\">OTCPK:ALPMF</a>)(<a href=\"https://seekingalpha.com/symbol/ALPMY\" title=\"Astellas Pharma, Inc. ADR\">OTCPK:ALPMY</a>).</li>\n<li>Astellas plans to launch the product in H1 2017.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231488\" data-linked=\"Ironwood&#39;s Linzess OK&#39;d in Japan to treat IBS-C; shares up 3%\" data-tweet=\"$IRWD $IRWD $ALPMF - Ironwood&#39;s Linzess OK&#39;d in Japan to treat IBS-C; shares up 3% https://seekingalpha.com/news/3231488-ironwoods-linzess-okd-in-japan-to-treat-ibs-c-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3231488-ironwoods-linzess-okd-in-japan-to-treat-ibs-c-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231487\" data-ts=\"1482171829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WHLR\" target=\"_blank\">WHLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231487-wheeler-real-estate-investment-trust-completes-21st-acquisition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wheeler Real Estate Investment Trust completes 21st acquisition</a></h4><ul>     <li>Wheeler Real Estate Investment Trust (<a href=\"https://seekingalpha.com/symbol/WHLR\" title=\"Wheeler Real Estate Investment Trust\">WHLR</a> <font color=\"green\">+3.2%</font>) closed on the acquisition of a single-story grocery- anchored shopping center of Village of Martinsville for $23.53M.</li>\n<li>The acquired property contains 297,950 of rentable sq. ft. is 97% occupied and anchored by five prominent retailers.</li>\n<li>The acquisition value is financed using a combination of cash and the key bank credit facility with an interest rate of 30 day LIBOR plus 250bps.</li>\n<li>The cap rate on Village of Martinsville was 8.25%, and the loan-to-value was 65%.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231487\" data-linked=\"Wheeler Real Estate Investment Trust completes 21st acquisition\" data-tweet=\"$WHLR - Wheeler Real Estate Investment Trust completes 21st acquisition https://seekingalpha.com/news/3231487-wheeler-real-estate-investment-trust-completes-21st-acquisition?source=tweet\" data-url=\"https://seekingalpha.com/news/3231487-wheeler-real-estate-investment-trust-completes-21st-acquisition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231486\" data-ts=\"1482171723\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCLI\" target=\"_blank\">BCLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231486-brainstorm-readies-late-stage-nurown-study-in-als-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brainstorm readies late-stage NurOwn study in ALS; shares up 4%</a></h4><ul>\n<li>Thinly traded nano cap Brainstorm Therapeutics (<a href=\"https://seekingalpha.com/symbol/BCLI\" title=\"BrainStorm Cell Therapeutics Inc.\">BCLI</a> <font color=\"green\">+3.7%</font>) is up on a 12x surge in volume in response to its announcement it has reached general agreement with the FDA on the key elements of a Phase 3 study assessing NurOwn in patients with amyotrophic lateral sclerosis (ALS). The randomized, double-blind, placebo-controlled trial should commence in Q2 2017.</li>\n<li>The company also announces plans to submit an application in Israel that will allow patient access to NurOwn.</li>\n<li>\n<a href=\"http://www.brainstorm-cell.com/index.php/science-technology/nurown%E2%84%A2\" target=\"_blank\">NurOwn </a>cells are mesenchymal stem cells that have been induced, via the company's proprietary methods, to secrete a variety of neurotrophic factors.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231486\" data-linked=\"Brainstorm readies late-stage NurOwn study in ALS; shares up 4%\" data-tweet=\"$BCLI - Brainstorm readies late-stage NurOwn study in ALS; shares up 4% https://seekingalpha.com/news/3231486-brainstorm-readies-late-stage-nurown-study-in-als-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3231486-brainstorm-readies-late-stage-nurown-study-in-als-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231474\" data-ts=\"1482171126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLED\" target=\"_blank\">OLED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231474-j-p-morgan-observes-oled-industry-growth-for-2017\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.P. Morgan observes OLED industry growth for 2017</a></h4><ul>\n<li>Calculating a $20B industry figure, firm cites increasing capital expenditures primarily out of Samsung Electronics as indicator.</li>\n<li>\n<em><strong>N.B.</strong></em> Samsung Electronics business represents an estimated (supply chain data) 76% of Universal Display (<a href=\"https://seekingalpha.com/symbol/OLED\" title=\"Universal Display Corporation\">OLED</a> <font color=\"green\">+2.9%</font>) revenue.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231474\" data-linked=\"J.P. Morgan observes OLED industry growth for 2017\" data-tweet=\"$OLED - J.P. Morgan observes OLED industry growth for 2017 https://seekingalpha.com/news/3231474-j-p-morgan-observes-oled-industry-growth-for-2017?source=tweet\" data-url=\"https://seekingalpha.com/news/3231474-j-p-morgan-observes-oled-industry-growth-for-2017\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231478\" data-ts=\"1482170410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231478-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AWH' title='Allied World Assurance Company Holdings, AG'>AWH</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CLMS' title='Calamos Asset Management, Inc.'>CLMS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CIA' title='Citizens, Inc.'>CIA</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/DGICA' title='Donegal Group, Inc.'>DGICA</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AMBC' title='Ambac Financial'>AMBC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/AAMC' title='Altisource Asset Management Corp'>AAMC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='red'>-7%</font>. WMIH <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231478\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$AWH $CLMS $CIA - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3231478-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3231478-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231483\" data-ts=\"1482170278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USCR\" target=\"_blank\">USCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231483-trumps-policies-will-benefit-not-until-2018minus-19-us-concrete-ceo-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump&#39;s policies will benefit but not until 2018-19, US Concrete CEO says</a></h4><ul>\n<li>US Concrete (<a href=\"https://seekingalpha.com/symbol/USCR\" title=\"US Concrete Inc.\">USCR</a> <font color=\"green\">+2.7%</font>) enjoys strong gains after CEO Bill Sandbrook tells CNBC he is <a href=\"http://www.cnbc.com/2016/12/19/we-wont-see-trump-policy-benefits-until-2018-or-2019-us-concrete-ceo.html\" target=\"_blank\">optimistic</a> about Pres.-elect Trump's economic and infrastructure spending plans, although he says tangible benefits may not be seen until 2018 or 2019.</li>\n<li>Still, considering that one of Trump's first campaign promises upon being elected was to boost infrastructure spending, Sandbrook says he is not worried about the chance that those plans fail to make it through  Congress.</li>\n<li>The CEO says 15% of USCR's revenue comes from infrastructure and 61% from commercial projects.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231483\" data-linked=\"Trump&#39;s policies will benefit but not until 2018-19, US Concrete CEO says\" data-tweet=\"$USCR - Trump&#39;s policies will benefit but not until 2018-19, US Concrete CEO says https://seekingalpha.com/news/3231483-trumps-policies-will-benefit-not-until-2018minus-19-us-concrete-ceo-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3231483-trumps-policies-will-benefit-not-until-2018minus-19-us-concrete-ceo-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231475\" data-ts=\"1482169644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231475-mid-day-top-10-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mid-day Top 10 Gainers / Losers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+68%</font>. <a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/STRP' title='Straight Path Communications Inc.'>STRP</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CXRX-OLD' title='Concordia International Corp'>CXRX-OLD</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CLMS' title='Calamos Asset Management, Inc.'>CLMS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/AMBC' title='Ambac Financial'>AMBC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/VLTC' title='Voltari Corporation'>OTC:VLTC</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/LIFE' title='aTyr Pharma'>LIFE</a> <font color='red'>-13%</font>. COOL <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SAUC' title='Diversified Restaurant Holdings'>SAUC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CGNT' title='Cogentix Medical, Inc.'>CGNT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231475\" data-linked=\"Mid-day Top 10 Gainers / Losers\" data-tweet=\"$XGTI-OLD $LOXO $GSAT - Mid-day Top 10 Gainers / Losers https://seekingalpha.com/news/3231475-mid-day-top-10-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3231475-mid-day-top-10-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231473\" data-ts=\"1482169076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STVVY\" target=\"_blank\">STVVY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231473-china-digital-tv-holders-approve-super-tv-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Digital TV holders approve Super TV sale</a></h4><ul>   <li>At an extraordinary shareholder meeting today, China Digital TV (<a href=\"https://seekingalpha.com/symbol/STV\" target=\"_blank\">STV</a> <font color=\"red\">-2.5%</font>) approved the sale of its CA, Network Broadcasting Platform and Video on Demand businesses via the sale of its interest in Beijing Super TV.</li>    <li>The company had set up a <a href=\"https://seekingalpha.com/news/3221801-china-digital-tv-sets-management-super-tv-buyout-90m-payment\" target=\"_blank\">management/Super TV buyout</a> in November, involving a $90M payment. China Digital TV unit Golden Benefit Technology reached an equity-transfer deal with ChangxingBao LiRuiXin Technology, which is an LLC that includes China Digital chief Jianhua Zhu as well as Super TV President Dong Li.</li>    <li>China Digital also held its ordinary annual general meeting today, at which it approved the re-election of Jianyue Pan and Songzuo Xiang to three-year terms as Class III directors.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231473\" data-linked=\"China Digital TV holders approve Super TV sale\" data-tweet=\"$STVVY - China Digital TV holders approve Super TV sale https://seekingalpha.com/news/3231473-china-digital-tv-holders-approve-super-tv-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3231473-china-digital-tv-holders-approve-super-tv-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231471\" data-ts=\"1482168914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNVA\" target=\"_blank\">RNVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231471-rennova-health-prices-equity-offering-shares-slump-30\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rennova Health prices equity offering; shares slump 30%</a></h4><ul>\n<li>Rennova Health (<a href=\"https://seekingalpha.com/symbol/RNVA\" title=\"Rennova Health, Inc.\">OTCPK:RNVA</a> <font color=\"red\">-30.4%</font>) prices its public offering of 12,350 shares of Series H Convertible Preferred Stock at $1,000. Each preferred shares is convertible into 11,111 common shares at $0.09.</li>\n<li>Gross proceeds will be $12.35M. Net proceeds of ~$8.3M will fund the redemption of certain outstanding shares of the company's Series G Convertible Preferred Stock.</li>\n<li>Closing date is December 20.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231471\" data-linked=\"Rennova Health prices equity offering; shares slump 30%\" data-tweet=\"$RNVA - Rennova Health prices equity offering; shares slump 30% https://seekingalpha.com/news/3231471-rennova-health-prices-equity-offering-shares-slump-30?source=tweet\" data-url=\"https://seekingalpha.com/news/3231471-rennova-health-prices-equity-offering-shares-slump-30\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231468\" data-ts=\"1482168344\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231468-portola-nabs-50m-in-new-capital-from-pfizer-and-bristol-myers-to-support-andexxa-development\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola nabs $50M in new capital from Pfizer and Bristol-Myers to support AndexXa development; shares up 11%</a></h4><ul>\n<li>Portola Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/PTLA\" title=\"Portola Pharmaceuticals\">PTLA</a> <font color=\"green\">+11%</font>) heads north on slightly higher volume in response to its announcement that is has inked an unsecured $50M loan agreement with Pfizer (<a href=\"https://seekingalpha.com/symbol/PFE\" title=\"Pfizer Inc.\">PFE</a> <font color=\"green\">+0.2%</font>) and Bristol-Myers Squibb (<a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a> <font color=\"green\">+1.6%</font>) that will fund the continued development of Factor Xa antidote AndexXa (andexanet alfa).</li>\n<li>Under the terms of the agreement, the companies will each loan Portola $25M with principal and interest to be repaid through royalties on AndexXa commercial sales.</li>\n<li>Portola intends to resubmit its U.S. marketing application in 2017. It received a Complete Response Letter (CRL) from the FDA in August on its first try. Its marketing application in Europe is currently under review.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3204181-fda-rejects-portolas-andexxa-bla-shares-18-percent-premarket\" target=\"_blank\">FDA rejects Portola's AndexXa BLA; shares down 18% premarket</a> (Aug. 18)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231468\" data-linked=\"Portola nabs $50M in new capital from Pfizer and Bristol-Myers to support AndexXa development; shares up 11%\" data-tweet=\"$PTLA $PTLA $PFE - Portola nabs $50M in new capital from Pfizer and Bristol-Myers to support AndexXa development; shares up 11% https://seekingalpha.com/news/3231468-portola-nabs-50m-in-new-capital-from-pfizer-and-bristol-myers-to-support-andexxa-development?source=tweet\" data-url=\"https://seekingalpha.com/news/3231468-portola-nabs-50m-in-new-capital-from-pfizer-and-bristol-myers-to-support-andexxa-development\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231467\" data-ts=\"1482167887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231467-shooting-of-russian-ambassador-to-turkey-boosts-bid-for-treasurys\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shooting of Russian ambassador to Turkey boosts bid for Treasurys</a></h4><ul>\n<li>Russia's ambassador to Turkey was shot while attending an art exhibit in Ankara.</li>\n<li>Gold is seeing a little bit of action, as is the dollar, but the most noticeable move has been in U.S. Treasurys, with the 10-year yield down 6.2 basis points to 2.53% (was at about 2.56% when the news hit).</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/TLT\" title=\"iShares 20+ Year Treasury Bond ETF\">TLT</a> <font color=\"green\">+1.1%</font>, <a href=\"https://seekingalpha.com/symbol/TBT\" title=\"ProShares UltraShort 20+ Year Treasury ETF\">TBT</a> <font color=\"red\">-2.2%</font>\n</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231457-turkish-stocks-rattled-report-russian-ambassador-shooting\" target=\"_blank\">Turkish stocks rattled after report on Russian ambassador shooting</a> (Dec. 19)</li>\n<li>\n<strong>Update at 12:27:</strong> The Russian ambassador has died, according to an advisor to Turkish President Recep Tayyip Erdogan.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231467\" data-linked=\"Shooting of Russian ambassador to Turkey boosts bid for Treasurys\" data-tweet=\"$TLT $TBT - Shooting of Russian ambassador to Turkey boosts bid for Treasurys https://seekingalpha.com/news/3231467-shooting-of-russian-ambassador-to-turkey-boosts-bid-for-treasurys?source=tweet\" data-url=\"https://seekingalpha.com/news/3231467-shooting-of-russian-ambassador-to-turkey-boosts-bid-for-treasurys\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231465\" data-ts=\"1482166959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WR\" target=\"_blank\">WR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231465-westar-energyminus-2_7-kansas-recommends-against-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Westar Energy -2.7%; Kansas recommends against sale</a></h4><ul><li>Westar Energy's (<a href='https://seekingalpha.com/symbol/WR' title='Westar Energy, Inc.'>WR</a> <font color='red'>-2.7%</font>) sale to Great Plains Energy (<a href='https://seekingalpha.com/symbol/GXP' title='Great Plains Energy Inc.'>GXP</a> <font color='green'>+0.2%</font>) isn't in the public interest, said Jeffrey McClanahan of the Kansas Corporation Commission, in testimony filed on Friday.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231465\" data-linked=\"Westar Energy -2.7%; Kansas recommends against sale\" data-tweet=\"$WR $WR $GXP - Westar Energy -2.7%; Kansas recommends against sale https://seekingalpha.com/news/3231465-westar-energyminus-2_7-kansas-recommends-against-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3231465-westar-energyminus-2_7-kansas-recommends-against-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231464\" data-ts=\"1482166805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231464-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>\n<li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/MTEX\" title=\"Mannatech, Incorporated\">MTEX</a> <font color=\"green\">+5%</font>. <a href=\"https://seekingalpha.com/symbol/RELV\" title=\"Reliv' International, Inc.\">RELV</a> <font color=\"green\">+8%</font>. <a href=\"https://seekingalpha.com/symbol/AVP\" title=\"Avon Products, Inc.\">AVP</a> <font color=\"green\">+5%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/JAKK\" title=\"JAKKS Pacific, Inc.\">JAKK</a> <font color=\"red\">-31%</font>. <a href=\"https://seekingalpha.com/symbol/VRS\" title=\"Verso Corporation\">VRS</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/PME\" title=\"Pingtan Marine Enterprise Ltd.\">PME</a> <font color=\"red\">-5%</font>. <a href=\"https://seekingalpha.com/symbol/DFBG-OLD\" title=\"Differential Brands Group Inc.\">DFBG-OLD</a> <font color=\"red\">-5%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231464\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$MTEX $RELV $AVP - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3231464-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3231464-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231454\" data-ts=\"1482166267\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231454-fda-oks-clovis-rucaparib-for-ovarian-cancer-shares-up-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Clovis&#39; rucaparib for ovarian cancer; shares up 15%</a></h4><ul>\n<li>TheStreet <a href=\"https://www.thestreet.com/story/13931168/1/clovis-oncology-secures-fda-approval-for-new-ovarian-cancer-drug.html\" target=\"_blank\">reports </a>that the FDA has just approved Clovis Oncology's (<a href=\"https://seekingalpha.com/symbol/CLVS\" title=\"Clovis Oncology\">CLVS</a> <font color=\"green\">+15.2%</font>) rucaparib, branded as Rubraca, for the treatment of patients with advanced BRCA-positive ovarian cancer (OC) who have received at least two prior lines of chemo.</li>\n<li>BRCA-positive OC accounts for 15 - 20% of the ~22.3K cases of OC diagnosed in the U.S. each year.</li>\n<li>\n<a href=\"http://clovisoncology.com/products-companion-diagnostics/rucaparib/\" target=\"_blank\">Rucaparib </a>is a small molecule poly ADP-ribose polymerase (PARP) inhibitor that specifically binds to PARP-1 and PARP-2. PARPs are proteins that play a key role in repairing single-strand breaks in DNA. By inhibiting their action, multiple DNA breaks form during the replication process in tumor cells that have the BRCA1, BRCA2 or PALB2 mutation which leads to cell death.</li>\n<li>Competitor TESARO (<a href=\"https://seekingalpha.com/symbol/TSRO\" title=\"Tesaro\">TSRO</a> <font color=\"red\">-2.4%</font>) eases a bit on the news. Its PARP candidate for OC is Phase 3-stage niraparib.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231454\" data-linked=\"FDA OKs Clovis&#39; rucaparib for ovarian cancer; shares up 15%\" data-tweet=\"$CLVS $CLVS $TSRO - FDA OKs Clovis&#39; rucaparib for ovarian cancer; shares up 15% https://seekingalpha.com/news/3231454-fda-oks-clovis-rucaparib-for-ovarian-cancer-shares-up-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3231454-fda-oks-clovis-rucaparib-for-ovarian-cancer-shares-up-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231461\" data-ts=\"1482166211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARR\" target=\"_blank\">ARR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231461-insider-buys-boost-armour-residential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insider buys boost Armour Residential</a></h4><ul><li>Co-CEOs <a href=\"https://seekingalpha.com/filing/3329005\" target=\"_blank\">Jeffrey Zimmer </a>and <a href=\"https://seekingalpha.com/filing/3329008\" target=\"_blank\">Scott Ulm</a> together purchased 15K shares of company stock at just under $21 each this morning.</li><li><a href='https://seekingalpha.com/symbol/ARR' title='ARMOUR Residential REIT, Inc.'>ARR</a>&nbsp;<font color='green'>+3.5%</font>&nbsp;to $21.23</li></ul><div class=\"tiny-share-widget\" data-id=\"3231461\" data-linked=\"Insider buys boost Armour Residential\" data-tweet=\"$ARR - Insider buys boost Armour Residential https://seekingalpha.com/news/3231461-insider-buys-boost-armour-residential?source=tweet\" data-url=\"https://seekingalpha.com/news/3231461-insider-buys-boost-armour-residential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231456\" data-ts=\"1482165457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOGO\" target=\"_blank\">GOGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231456-gogo-cfo-to-retire-2017s-end-cco-leaving-in-march\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gogo CFO to retire at 2017&#39;s end; CCO leaving in March</a></h4><ul>   <li>Changes are on the way to the leadership suite at Gogo (<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a> <font color='green'>+1.8%</font>) as its chief financial officer <a href=\"https://seekingalpha.com/filing/3328834\" target=\"_blank\">sets a 2017 retirement</a> and its chief commercial officer pursues another opportunity.</li>    <li>CFO and executive VP Norman Smagley will retire from those posts at the end of 2017, and in the meantime help find a successor and pursue an orderly transition.</li>    <li>Meanwhile, CCO and executive VP Ash ElDifrawi will leave his role March 31.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231456\" data-linked=\"Gogo CFO to retire at 2017&#39;s end; CCO leaving in March\" data-tweet=\"$GOGO - Gogo CFO to retire at 2017&#39;s end; CCO leaving in March https://seekingalpha.com/news/3231456-gogo-cfo-to-retire-2017s-end-cco-leaving-in-march?source=tweet\" data-url=\"https://seekingalpha.com/news/3231456-gogo-cfo-to-retire-2017s-end-cco-leaving-in-march\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231455\" data-ts=\"1482165075\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTGC\" target=\"_blank\">HTGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231455-hercules-capitalplus-2_4-on-strong-investment-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hercules Capital +2.4% on strong investment guidance</a></h4><ul>\n<li>Hercules (<a href=\"https://seekingalpha.com/symbol/HTGC\" title=\"Hercules Capital, Inc.\">HTGC</a> <font color=\"green\">+2.3%</font>) announces more than $200M of new debt and equity investments in Q4, and expects the yearly total to top $800M vs. $745M in 2015.</li>\n<li>In addition, a number of portfolio companies have hit key milestones, unlocking unfunded commitments, with the result being the company expecting to exceed the high end of its portfolio target of $1.35B.</li>\n<li>The debt portfolio is \"well-positioned\" for rate increases, with each 25 basis points boost in the Prime Rate expected to add $0.02 per share in NII.</li>\n<li>Shares <font color=\"green\">+2.4%</font>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231455\" data-linked=\"Hercules Capital +2.4% on strong investment guidance\" data-tweet=\"$HTGC - Hercules Capital +2.4% on strong investment guidance https://seekingalpha.com/news/3231455-hercules-capitalplus-2_4-on-strong-investment-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3231455-hercules-capitalplus-2_4-on-strong-investment-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231452\" data-ts=\"1482164929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOS\" target=\"_blank\">MOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231452-mosaic-vale-lower-following-2_5b-fertilizer-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mosaic, Vale lower following $2.5B fertilizer deal</a></h4><ul>     <li>Mosaic (<a href=\"https://seekingalpha.com/symbol/MOS\" title=\"The Mosaic Company\">MOS</a> <font color=\"red\">-4.6%</font>) and Vale (<a href=\"https://seekingalpha.com/symbol/VALE\" title=\"Vale S.A.\">VALE</a> <font color=\"red\">-3.5%</font>) are both trading lower after the ag giant buys most of the fertilizer chemicals business of the Brazilian miner in a <a href=\"https://seekingalpha.com/news/3231311-mosaic-buy-brazilian-fertilizer-maker-2_5b\" target=\"_blank\">cash and stock deal valued at $2.5B</a>.</li>     <li>MOS will pay for the deal with $1.25B in cash, which it plans to raise through debt, and 42.3M newly issued common shares, or a ~11% stake in the company.</li>     <li>Rumors had swirled for months that MOS could buy Vale's fertilizer business, with some reports <a href=\"https://seekingalpha.com/news/3210129-vale-plus-4-percent-talk-3b-fertilizer-unit-sale\" target=\"_blank\">speculating a $3B price tag</a>.</li>     <li>Analysts at Banco BTG Pactual estimate MOS is paying 8.6x the fertilizer division's EBITDA, which they say is \"<a href=\"http://www.reuters.com/article/us-vale-sa-m-a-mosaic-fertilizers-idUSKBN148142\" target=\"_blank\">an attractive multiple for Vale</a>.\"</li>\n<li>Brazil already is MOS's largest international market, generating $2.14B in net sales in 2015, or 24% of the company's total for the year.</li>     <li>Vale says it will retain its nitrogen and phosphate fertilizer assets in Cubatão, Brazil, which generated $108M in cash flow during 2015, but it expects to sell them in 2017.</li>     <li>Vale has been selling assets to help meet a $10B debt reduction target by next year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231452\" data-linked=\"Mosaic, Vale lower following $2.5B fertilizer deal\" data-tweet=\"$MOS $MOS $VALE - Mosaic, Vale lower following $2.5B fertilizer deal https://seekingalpha.com/news/3231452-mosaic-vale-lower-following-2_5b-fertilizer-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3231452-mosaic-vale-lower-following-2_5b-fertilizer-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231447\" data-ts=\"1482164571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231447-biocryst-pharma-builds-on-fridays-up-move-shares-ahead-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioCryst Pharma builds on Friday&#39;s up move, shares ahead 13%</a></h4><ul>\n<li>BioCryst Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/BCRX\" title=\"BioCryst Pharmaceuticals, Inc.\">BCRX</a> <font color=\"green\">+13.1%</font>) continues its upward momentum. Shares are up over <font color=\"green\">23%</font> since Friday forcing short sellers to cover.</li>\n<li>On Friday, JMP Securities upgraded the stock to Outperform from Market Perform with a $10 (43% upside) price target.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231447\" data-linked=\"BioCryst Pharma builds on Friday&#39;s up move, shares ahead 13%\" data-tweet=\"$BCRX - BioCryst Pharma builds on Friday&#39;s up move, shares ahead 13% https://seekingalpha.com/news/3231447-biocryst-pharma-builds-on-fridays-up-move-shares-ahead-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3231447-biocryst-pharma-builds-on-fridays-up-move-shares-ahead-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231440\" data-ts=\"1482163449\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BREW\" target=\"_blank\">BREW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231440-craft-brew-alliance-continues-to-run-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Craft Brew Alliance continues to run higher</a></h4><ul> <li>Craft Brew Alliance (<a href=\"https://seekingalpha.com/symbol/BREW\" title=\"Craft Brew Alliance Inc\">BREW</a> <font color=\"green\">+5.1%</font>) continues to rally after the company announced last week that it took a 24.5% stake in Wynwood Brewing out of Miami.</li> <li>Wynwood thinks it can increase its presence in Florida by using Craft Brew's production and marketing muscle.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3231440\" data-linked=\"Craft Brew Alliance continues to run higher\" data-tweet=\"$BREW - Craft Brew Alliance continues to run higher https://seekingalpha.com/news/3231440-craft-brew-alliance-continues-to-run-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3231440-craft-brew-alliance-continues-to-run-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231435\" data-ts=\"1482163018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSN\" target=\"_blank\">MSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231435-emerson-radio-flies-after-announcing-new-buyback-allowance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emerson Radio flies after announcing new buyback allowance</a></h4><ul>     <li>Emerson Radio (<a href=\"https://seekingalpha.com/symbol/MSN\" title=\"Emerson Radio Corp\">MSN</a> <font color=\"green\">+14.1%</font>) spikes after the company announces that a new share repurchase agreement of up to $5M worth of its common stock was approved.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3231435\" data-linked=\"Emerson Radio flies after announcing new buyback allowance\" data-tweet=\"$MSN - Emerson Radio flies after announcing new buyback allowance https://seekingalpha.com/news/3231435-emerson-radio-flies-after-announcing-new-buyback-allowance?source=tweet\" data-url=\"https://seekingalpha.com/news/3231435-emerson-radio-flies-after-announcing-new-buyback-allowance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231427\" data-ts=\"1482162158\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEN\" target=\"_blank\">LEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231427-lennars-3-gain-leads-homebuilders-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lennar&#39;s 3% gain leads homebuilders higher</a></h4><ul>\n<li>Lennar's (<a href=\"https://seekingalpha.com/symbol/LEN\" title=\"Lennar Corporation\">LEN</a> <font color=\"green\">+3.0%</font>) FQ4 <a href=\"https://seekingalpha.com/news/3231320-lennar-tops-estimates-margins-slip-one-year-ago\" target=\"_blank\">topped estimates</a> by plenty, with deliveries, new orders, and ASPs all higher.</li>\n<li>The iShares U.S. Home Construction ETF's (<a href=\"https://seekingalpha.com/symbol/ITB\" title=\"iShares U.S. Home Construction ETF\">ITB</a> <font color=\"green\">+1.3%</font>) advance is beating the S&amp;P's <font color=\"green\">0.35% gain</font>.</li>\n<li>Individual names: Toll Brothers (<a href=\"https://seekingalpha.com/symbol/TOL\" title=\"Toll Brothers Inc.\">TOL</a> <font color=\"green\">+1.7%</font>), Pulte (<a href=\"https://seekingalpha.com/symbol/PHM\" title=\"PulteGroup, Inc.\">PHM</a> <font color=\"green\">+2.3%</font>), Hovnanian (<a href=\"https://seekingalpha.com/symbol/HOV\" title=\"Hovnanian Enterprises, Inc.\">HOV</a> <font color=\"green\">+3.6%</font>), D.R. Horton (<a href=\"https://seekingalpha.com/symbol/DHI\" title=\"D. R. Horton Inc.\">DHI</a> <font color=\"green\">+1.7%</font>), KB Home (<a href=\"https://seekingalpha.com/symbol/KBH\" title=\"KB Home\">KBH</a> <font color=\"green\">+2.1%</font>), Meritage (<a href=\"https://seekingalpha.com/symbol/MTH\" title=\"Meritage Homes Corporation\">MTH</a> <font color=\"green\">+1.4%</font>).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231427\" data-linked=\"Lennar&#39;s 3% gain leads homebuilders higher\" data-tweet=\"$LEN $LEN $ITB - Lennar&#39;s 3% gain leads homebuilders higher https://seekingalpha.com/news/3231427-lennars-3-gain-leads-homebuilders-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3231427-lennars-3-gain-leads-homebuilders-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231411\" data-ts=\"1482159911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231411-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CXRX-OLD' title='Concordia International Corp'>CXRX-OLD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/WINT' title='Windtree Therapeutics, Inc.'>OTCQB:WINT</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LIFE' title='aTyr Pharma'>LIFE</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CBMG' title='Cellular Biomedicine Group, Inc.'>CBMG</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231411\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CXRX-OLD $LOXO $OCUL - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3231411-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3231411-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231410\" data-ts=\"1482159846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RLGY\" target=\"_blank\">RLGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231410-realogyplus-4_5-on-wedbush-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Realogy +4.5% on Wedbush upgrade</a></h4><ul>\n<li>Realogy (NYSE:<a href=\"https://seekingalpha.com/symbol/RLGY\" title=\"Realogy Holdings\">RLGY</a>) is <font color=\"green\">higher by more than 16%</font> since the election, but is still <font color=\"red\">lower by 27%</font> YTD. Citing the depressed valuation and optimism for existing home sales in 2017 and 2018, analyst Jason Weaver upgrades to Outperform from Neutral.</li>\n<li>His $32 price target suggests <font color=\"green\">25% upside</font>.</li>\n<li>The stock's <font color=\"green\">higher by 4.5%</font> in early acton.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231410\" data-linked=\"Realogy +4.5% on Wedbush upgrade\" data-tweet=\"$RLGY - Realogy +4.5% on Wedbush upgrade https://seekingalpha.com/news/3231410-realogyplus-4_5-on-wedbush-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3231410-realogyplus-4_5-on-wedbush-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231408\" data-ts=\"1482159531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DB\" target=\"_blank\">DB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231408-reuters-deutsche-bank-mortgage-settlement-near-citi-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Deutsche Bank mortgage settlement near; Citi downgrades</a></h4><ul>\n<li>A deal between the German lender and the DOJ could be wrapped by Christmas, <a href=\"http://www.streetinsider.com/Litigation/Deutsche+Bank+could+settle+U.S.+penalty+this+week%3A+source/12354885.html\" target=\"_blank\">according to the report</a>, and looks like it will be for far less than the bank-wrecking $14B originally floated.</li>\n<li>As for the stock, Deutsche (<a href=\"https://seekingalpha.com/symbol/DB\" title=\"Deutsche Bank AG\">DB</a> <font color=\"red\">-2.2%</font>) is lower in early action in what looks to be a response to a downgrade to Sell from Citi. Deutsche's <font color=\"green\">41% post-election surge </font>is too far too fast, says Citi, noting far more subdued moves from European peers.</li>\n<li>Citi prefers the Swiss lenders, with Credit Suisse (<a href=\"https://seekingalpha.com/symbol/CS\" title=\"Credit Suisse Group AG\">CS</a> <font color=\"red\">-0.2%</font>) a top pick given all the room for management to make improvements. UBS (<a href=\"https://seekingalpha.com/symbol/UBS\" title=\"UBS Group AG\">UBS</a> <font color=\"green\">+0.2%</font>) is also rated a Buy, but doesn't have as many short-term catalysts.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231408\" data-linked=\"Reuters: Deutsche Bank mortgage settlement near; Citi downgrades\" data-tweet=\"$DB $DB $CS - Reuters: Deutsche Bank mortgage settlement near; Citi downgrades https://seekingalpha.com/news/3231408-reuters-deutsche-bank-mortgage-settlement-near-citi-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3231408-reuters-deutsche-bank-mortgage-settlement-near-citi-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231407\" data-ts=\"1482159068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSEM\" target=\"_blank\">TSEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231407-needham-company-restates-tower-semiconductor-buy-2017\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham &amp; Company restates Tower Semiconductor at Buy into 2017</a></h4><ul>\n<li>Citing Tower Semiconductor (<a href=\"https://seekingalpha.com/symbol/TSEM\" title=\"Tower Semiconductor Ltd.\">TSEM</a> <font color=\"green\">+1.3%</font>) a top pick for the upcoming year, <a href=\"http://www.streetinsider.com/Analyst+Comments/Tower+Semiconductor+%28TSEM%29%3A+Top+Pick+for+2017+-+Needham/12354222.html\" target=\"_blank\">analyst Rajvindra Gill</a> notes consideration for increasing company share within CMOS image sensor and RF front-end module markets. and a continuing escalation of utilization rates across all fabrications.</li>\n<li>Price target retained at $25 (current price $19.25).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231407\" data-linked=\"Needham &amp; Company restates Tower Semiconductor at Buy into 2017\" data-tweet=\"$TSEM - Needham &amp; Company restates Tower Semiconductor at Buy into 2017 https://seekingalpha.com/news/3231407-needham-company-restates-tower-semiconductor-buy-2017?source=tweet\" data-url=\"https://seekingalpha.com/news/3231407-needham-company-restates-tower-semiconductor-buy-2017\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231393\" data-ts=\"1482158678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOXO\" target=\"_blank\">LOXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231393-loxo-oncologys-larotrectinib-on-accelerated-regulatory-path-nda-on-tap-in-late-2017-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loxo Oncology&#39;s larotrectinib on accelerated regulatory path; NDA on tap in late 2017/early 2018; shares up 14%</a></h4><ul>\n<li>Loxo Oncology (<a href=\"https://seekingalpha.com/symbol/LOXO\" title=\"Loxo Oncology\">LOXO</a> <font color=\"green\">+14.2%</font>) perks on the heels of its announcement that it is positioned to submit a New Drug Application (NDA) seeking approval of LOXO-101 (larotrectinib) for the treatment of solid tumors with NTRK-fusion proteins as early as Q4 2017.</li>\n<li>The company's larotrectinib program (two Phase 1s and one Phase 2) is ~85% enrolled. The primary endpoint of the Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02576431?term=loxo-101&amp;rank=3\" target=\"_blank\">NAVIGATE </a>study is best overall response. Top-line data are expected in H2 2017.</li>\n<li>\n<a href=\"https://www.loxooncology.com/pipeline#loxo-101\" target=\"_blank\">LOXO-101</a> inhibits a group of enzymes called tropomyosin receptor kinases (TRK), a group of proteins that play a key role in cellular communications. Cancers hijack these communication pathways to send messages the cells to grow, change or survive. Those characterized by these alterations, termed NTRK fusions, are the therapeutic targets for LOXO-101.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231393\" data-linked=\"Loxo Oncology&#39;s larotrectinib on accelerated regulatory path; NDA on tap in late 2017/early 2018; shares up 14%\" data-tweet=\"$LOXO - Loxo Oncology&#39;s larotrectinib on accelerated regulatory path; NDA on tap in late 2017/early 2018; shares up 14% https://seekingalpha.com/news/3231393-loxo-oncologys-larotrectinib-on-accelerated-regulatory-path-nda-on-tap-in-late-2017-early?source=tweet\" data-url=\"https://seekingalpha.com/news/3231393-loxo-oncologys-larotrectinib-on-accelerated-regulatory-path-nda-on-tap-in-late-2017-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231387\" data-ts=\"1482158623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKER\" target=\"_blank\">AKER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231387-akers-biosciences-inks-three-year-deal-gnyha-for-heparin-pf4-rapid-test-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akers Biosciences inks three year deal with GNYHA for Heparin PF4 Rapid Test; shares up 4%</a></h4><ul> <li>Akers Biosciences (<a href=\"https://seekingalpha.com/symbol/AKER\" title=\"Akers Biosciences Inc.\">AKER</a>) announces that it has signed a three-year agreement with the Greater New York Hospital Association (GNYHA) to introduce the Company's flagship rapid tests for <a href=\"https://en.wikipedia.org/wiki/Heparin-induced_thrombocytopenia\" target=\"_blank\">heparin-induced thrombocytopenia</a> (HIT) across GNYHA's network of over 300 member hospitals.</li> <li>Akers Bio's <a href=\"http://www.akersbio.com/products/clinical-diagnostics/heparin-induced-thrombocytopenia-and-pf4-antibodies\" target=\"_blank\">PIFA Heparin/PF4 Rapid Assay</a> and PIFA PLUSS PF4 tests were designed to quickly determine at or near the point-of-care if a patient being treated with the widely used blood thinner heparin may be developing HIT.</li>\n<li>Akers Bio believes its rapid tests have the capacity to provide dramatic cost savings for hospitals when compared to traditional testing methodologies for detecting HIT.</li> <li>Under the terms of the agreement, Akers Bio's PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 tests will be evaluated at two GNYHA hospitals before system-wide marketing begins.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231387\" data-linked=\"Akers Biosciences inks three year deal with GNYHA for Heparin PF4 Rapid Test; shares up 4%\" data-tweet=\"$AKER - Akers Biosciences inks three year deal with GNYHA for Heparin PF4 Rapid Test; shares up 4% https://seekingalpha.com/news/3231387-akers-biosciences-inks-three-year-deal-gnyha-for-heparin-pf4-rapid-test-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3231387-akers-biosciences-inks-three-year-deal-gnyha-for-heparin-pf4-rapid-test-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231390\" data-ts=\"1482157861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUBS\" target=\"_blank\">HUBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231390-hubspot-upgraded-to-strong-buy-raymond-james\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HubSpot upgraded to Strong Buy at Raymond James</a></h4><ul>\n<li>Analyst Terry Tillman considers recent weakness overblown and top line growth at HubSpot (<a href=\"https://seekingalpha.com/symbol/HUBS\" title=\"HubSpot, Inc.\">HUBS</a> <font color=\"green\">+4.7%</font>) to continue at 30%+ levels for several years.</li>\n<li>Recalculates target from $60 to $64 (current price $47.40).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231390\" data-linked=\"HubSpot upgraded to Strong Buy at Raymond James\" data-tweet=\"$HUBS - HubSpot upgraded to Strong Buy at Raymond James https://seekingalpha.com/news/3231390-hubspot-upgraded-to-strong-buy-raymond-james?source=tweet\" data-url=\"https://seekingalpha.com/news/3231390-hubspot-upgraded-to-strong-buy-raymond-james\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231388\" data-ts=\"1482157445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231388-globalstarplus-29-fcc-circulates-revised-proposal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar +29% as FCC circulates revised proposal</a></h4><ul>     <li>Globalstar (NYSEMKT:<a href=\"https://seekingalpha.com/symbol/GSAT\" title=\"Globalstar, Inc.\">GSAT</a>) is <font color=\"green\">up 29%</font> premarket, seeing its highest quotes since September, after weekend word that the FCC has put the company's revised Wi-Fi proposal on circulation.</li>     <li>The FCC drafted a new Proposed Order in response to an Dec. 7 revision of the company's proposal, which Globalstar says offers <a href=\"http://www.globalstar.com/en/ir/docs/Statement_12_16_16_FINAL.pdf\" target=\"_blank\">significant protections</a> to adjacent operations as it seeks to expand the supply of broadband spectrum.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231388\" data-linked=\"Globalstar +29% as FCC circulates revised proposal\" data-tweet=\"$GSAT - Globalstar +29% as FCC circulates revised proposal https://seekingalpha.com/news/3231388-globalstarplus-29-fcc-circulates-revised-proposal?source=tweet\" data-url=\"https://seekingalpha.com/news/3231388-globalstarplus-29-fcc-circulates-revised-proposal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231385\" data-ts=\"1482157406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLMS\" target=\"_blank\">CLMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231385-calamos-asset-management-going-private-12-premium\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calamos Asset Management going private at 12% premium</a></h4><ul>\n<li>Calamos Asset Management (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CLMS\" title=\"Calamos Asset Management, Inc.\">CLMS</a>) Chairman John Calamos and CEO John Koudounis have agreed to buy all shares not currently owned for $8.25 in cash each. That's a <font color=\"green\">12% premium</font> to Friday's close.</li>\n<li>A special committee formed by the board has been studying the deal since October and gives its blessing.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231385\" data-linked=\"Calamos Asset Management going private at 12% premium\" data-tweet=\"$CLMS - Calamos Asset Management going private at 12% premium https://seekingalpha.com/news/3231385-calamos-asset-management-going-private-12-premium?source=tweet\" data-url=\"https://seekingalpha.com/news/3231385-calamos-asset-management-going-private-12-premium\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231384\" data-ts=\"1482157245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LRCX\" target=\"_blank\">LRCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231384-goldman-sachs-upgrades-lam-research-downgrades-applied-materials-initiates-kla-tencor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs upgrades Lam Research, downgrades Applied Materials, initiates KLA-Tencor</a></h4><ul>\n<li>Analyst Toshiya Hari <a href=\"http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Upgrades+Lam+Research+%28LRCX%29+and+Adds+to+Conviction+Buy+List/12354414.html\" target=\"_blank\">raises Lam Research</a> (NASDAQ:<a href=\"https://seekingalpha.com/symbol/LRCX\" title=\"Lam Research Corporation\">LRCX</a>) to Conviction Buy with a $125 target (current price $104.45) on continuing 3D NAND strength and indication share gains in logic, potentially at Intel, are growing. Considers downside volatility a lessened risk over the upcoming 2-3 years due to a diversified end-demand landscape and prospects for China. Further notes Lam Research's positioning, upside potential and improvements which may lead to overall investor rerating.</li>\n<li>\n<a href=\"http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Applied+Materials+%28AMAT%29+to+Neutral/12353956.html\" target=\"_blank\">Lowers Applied Materials</a> (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AMAT\" title=\"Applied Materials, Inc.\">AMAT</a>) to Neutral with a $35 (current price $32.18) target on fair risk-return evaluation.</li>\n<li>\n<a href=\"http://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Goldman+Sachs+Starts+KLA-Tencor+%28KLAC%29+at+Buy/12353950.html\" target=\"_blank\">Starts Buy coverage</a> on KLA-Tencor (NASDAQ:<a href=\"https://seekingalpha.com/symbol/KLAC\" title=\"KLA-Tencor Corporation\">KLAC</a>) with a $90 target, citing the company's underperformance in recent years relative to peers and outperformance he expects in those to come on product cycle, 7nm foundry ramp and China tailwinds.</li>\n<li>\n<strong>Pre-market</strong>: Lam Research <font color=\"green\">+1.41%</font>, Applied Materials <font color=\"red\">-0.49%</font>, KLA-Tencor <font color=\"green\">+1.36%</font>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231384\" data-linked=\"Goldman Sachs upgrades Lam Research, downgrades Applied Materials, initiates KLA-Tencor\" data-tweet=\"$LRCX $LRCX $AMAT - Goldman Sachs upgrades Lam Research, downgrades Applied Materials, initiates KLA-Tencor https://seekingalpha.com/news/3231384-goldman-sachs-upgrades-lam-research-downgrades-applied-materials-initiates-kla-tencor?source=tweet\" data-url=\"https://seekingalpha.com/news/3231384-goldman-sachs-upgrades-lam-research-downgrades-applied-materials-initiates-kla-tencor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231382\" data-ts=\"1482157103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231382-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/BCLI' title='BrainStorm Cell Therapeutics Inc.'>BCLI</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/AWH' title='Allied World Assurance Company Holdings, AG'>AWH</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231382\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$XGTI-OLD $GSAT $BCLI - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3231382-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3231382-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231379\" data-ts=\"1482156755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231379-catalyst-bio-nabs-manufacturing-rights-to-factor-viia-for-hemophilia-shares-ahead-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio nabs manufacturing rights to Factor VIIa for hemophilia; shares ahead 4% premarket</a></h4><ul>\n<li>Catalyst Biosciences (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CBIO\" title=\"Catalyst Biosciences, Inc.\">CBIO</a>) is up <font color=\"green\">4%</font> premarket on increased volume in response to its announcement that it has secured all rights to the manufacturing process for marzeptacog alfa (activated)(formerly known as CB 813d) from Pfizer's (NYSE:<a href=\"https://seekingalpha.com/symbol/PFE\" title=\"Pfizer Inc.\">PFE</a>) Wyeth unit. It now has complete cGMP manufacturing capabilities.</li>\n<li>Marzeptacog alfa (activated) is a next-generation Factor VIIa product designed for long-term, subcutaneous prophylaxis in hemophilia patients with inhibitors.</li>\n<li>The company has also inked a fill-finish services agreement with Symbiosis Pharmaceutical Services Limited to supply marzeptacog alfa (activated) for clinical trials.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231379\" data-linked=\"Catalyst Bio nabs manufacturing rights to Factor VIIa for hemophilia; shares ahead 4% premarket\" data-tweet=\"$CBIO $CBIO $PFE - Catalyst Bio nabs manufacturing rights to Factor VIIa for hemophilia; shares ahead 4% premarket https://seekingalpha.com/news/3231379-catalyst-bio-nabs-manufacturing-rights-to-factor-viia-for-hemophilia-shares-ahead-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231379-catalyst-bio-nabs-manufacturing-rights-to-factor-viia-for-hemophilia-shares-ahead-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231376\" data-ts=\"1482156664\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAS\" target=\"_blank\">HAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231376-trouble-in-toyland\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trouble in toyland?</a></h4><ul>\n<li>A stinging cut in guidance from JAKKS Pacific could weigh heavily on Hasbro (NASDAQ:<a href=\"https://seekingalpha.com/symbol/HAS\" title=\"Hasbro, Inc.\">HAS</a>) and Mattel (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MAT\" title=\"Mattel, Inc.\">MAT</a>) as investors eye the key holiday season.</li>\n<li>Hasbro and Mattel have traded weakly over the last month on some trepidation over Q4 numbers, trailing the S&amp;P 500 and broad retail ETF averages.</li>\n<li>Shares of JAKK are <font color=\"red\">down 18%</font> in premarket action, while Hasbo (<a href=\"https://seekingalpha.com/symbol/HAS\" title=\"Hasbro, Inc.\">HAS</a>) is <font color=\"red\">off 0.70%</font> and Mattel is <font color=\"red\">1.11% lower</font>.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231280-jakks-pacific-lowers-guidance\" target=\"_blank\">JAKKS Pacific lowers guidance</a> (Dec. 18)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231373-sharp-drop-jakks-pacific-guidance-cut\" target=\"_blank\">Sharp drop for JAKKS Pacific after guidance cut</a> (Dec. 19)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231376\" data-linked=\"Trouble in toyland?\" data-tweet=\"$HAS $HAS $MAT - Trouble in toyland? https://seekingalpha.com/news/3231376-trouble-in-toyland?source=tweet\" data-url=\"https://seekingalpha.com/news/3231376-trouble-in-toyland\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231373\" data-ts=\"1482156413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAKK\" target=\"_blank\">JAKK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231373-sharp-drop-for-jakks-pacific-after-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sharp drop for JAKKS Pacific after guidance cut</a></h4><ul> <li>JAKKS Pacific (NASDAQ:<a href=\"https://seekingalpha.com/symbol/JAKK\" title=\"JAKKS Pacific, Inc.\">JAKK</a>) are getting crushed in early trading after the company lowered guidance sharply over the weekend.</li> <li>B. Riley says the company could be in \"real trouble\" if Christmas sales disappoint. The toy stock is rated at Neutral with a lowered PT of $5.</li> <li>BMO Capital Markets lowers its rating to Market Perform from Outperform.</li> <li>Piper Jaffray warns on the deleveraging impact of a lower level of sales. The firm drops JAKK to Neutral from Overweight and the PT is slashed to $6 from $11.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231280-jakks-pacific-lowers-guidance\" target=\"_blank\">JAKKS Pacific lowers guidance</a> (Dec. 18)</li>\n<li>Sources: Bloomberg and Marketbeat.com.</li>\n<li>JAKK <font color=\"red\">-18.44%</font> premarket to $5.75 on light volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231373\" data-linked=\"Sharp drop for JAKKS Pacific after guidance cut\" data-tweet=\"$JAKK - Sharp drop for JAKKS Pacific after guidance cut https://seekingalpha.com/news/3231373-sharp-drop-for-jakks-pacific-after-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3231373-sharp-drop-for-jakks-pacific-after-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231368\" data-ts=\"1482155916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OREX\" target=\"_blank\">OREX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231368-orexigen-inks-contrave-distribution-deal-in-middle-east-shares-up-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orexigen inks Contrave distribution deal in Middle East; shares up 17% premarket</a></h4><ul>\n<li>Orexigen Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OREX\" title=\"Orexigen Therapeutics, Inc.\">OREX</a>) is up <font color=\"green\">17%</font> premarket, albeit on only 500 shares, in response to its announcement that it has executed a commercialization and distribution agreement with Biologix FZCO for Contrave (naltrexone HCl/bupropion HCl prolonged release) covering 10 countries in the Middle East.</li>\n<li>Under the terms of the agreement, Biologix will be responsible for obtaining regulatory approvals and local product registrations in each country and all commercialization activities. Orexigen will supply the product at an agreed-to transfer price. Contrave should be available in certain countries beginning in Q3 2017.</li>\n<li>Specific financial terms  are not disclosed.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231368\" data-linked=\"Orexigen inks Contrave distribution deal in Middle East; shares up 17% premarket\" data-tweet=\"$OREX - Orexigen inks Contrave distribution deal in Middle East; shares up 17% premarket https://seekingalpha.com/news/3231368-orexigen-inks-contrave-distribution-deal-in-middle-east-shares-up-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231368-orexigen-inks-contrave-distribution-deal-in-middle-east-shares-up-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231345\" data-ts=\"1482154447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231345-fda-grants-breakthrough-therapy-designation-to-tonix-pharmaceuticals-tnxminus-102-sl-for\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA grants breakthrough therapy designation to Tonix Pharmaceuticals\u2019 TNX-102 SL for the treatment of PTSD; shares up 41% premarket</a></h4><ul> <li>Tonix Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/TNXP\" title=\"Tonix Pharmaceuticals Holding Corp.\">TNXP</a>) announces that the FDA has granted <a href=\"https://en.wikipedia.org/wiki/Breakthrough_therapy\" target=\"_blank\">Breakthrough Therapy</a> designation to <a href=\"http://www.tonixpharma.com/research-development/overview\" target=\"_blank\">TNX-102 SL</a> for the treatment of posttraumatic stress disorder (PTSD).</li>     <li>The benefits of Breakthrough Therapy designation include the eligibility for priority review of the New Drug Application (NDA) within six months instead of ten months and rolling submission of portions of the NDA, in addition to an organizational commitment involving FDA's senior managers contributing significant guidance.</li>  <li>Tonix held a successful End-of-Phase 2/Pre-Phase 3 meeting with the FDA in the Q3 2016, based on positive data from its 12-week randomized, double-blind, placebo-controlled Phase 2 AtEase study.  Tonix plans to begin enrolling patients into its first Phase 3 study, the HONOR study, in Q1 2017 after receiving FDA agreement on the study design and interim analysis plan.</li>    <li>TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an Investigational New Drug and has not been approved for any indication.</li>    <li>The FDA's Breakthrough Therapy designation is intended to expedite the development and review of a drug candidate that is planned for use to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.</li>\n<li>Shares are up <font color=\"green\">41%</font> premarket on robust volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231345\" data-linked=\"FDA grants breakthrough therapy designation to Tonix Pharmaceuticals\u2019 TNX-102 SL for the treatment of PTSD; shares up 41% premarket\" data-tweet=\"$TNXP - FDA grants breakthrough therapy designation to Tonix Pharmaceuticals\u2019 TNX-102 SL for the treatment of PTSD; shares up 41% premarket https://seekingalpha.com/news/3231345-fda-grants-breakthrough-therapy-designation-to-tonix-pharmaceuticals-tnxminus-102-sl-for?source=tweet\" data-url=\"https://seekingalpha.com/news/3231345-fda-grants-breakthrough-therapy-designation-to-tonix-pharmaceuticals-tnxminus-102-sl-for\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231352\" data-ts=\"1482153922\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVCR\" target=\"_blank\">NVCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231352-expanded-use-of-novocures-optune-okd-in-japan-shares-ahead-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Expanded use of Novocure&#39;s Optune OK&#39;d in Japan; shares ahead 8% premarket</a></h4><ul>\n<li>Novocure (NASDAQ:<a href=\"https://seekingalpha.com/symbol/NVCR\" title=\"NovoCure\">NVCR</a>) is up<font color=\"green\"> 8%</font> premarket, albeit on only 109 shares, in response to its announcement that the Japanese Ministry of Healthy, Labor and Welfare has approved Optune (NovoTTF-100A), its Tumor Treating Fields (TTFields) delivery system, for the treatment of adult patients with supra-tentorial glioblastoma (GBM) following maximal safe surgical resection and radiation therapy.</li>\n<li>The company says it is working on its application for public reimbursement for newly diagnosed GBM.</li>\n<li>Optune was approved in Japan for the treatment of recurrent GBM in March 2015.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231352\" data-linked=\"Expanded use of Novocure&#39;s Optune OK&#39;d in Japan; shares ahead 8% premarket\" data-tweet=\"$NVCR - Expanded use of Novocure&#39;s Optune OK&#39;d in Japan; shares ahead 8% premarket https://seekingalpha.com/news/3231352-expanded-use-of-novocures-optune-okd-in-japan-shares-ahead-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231352-expanded-use-of-novocures-optune-okd-in-japan-shares-ahead-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231350\" data-ts=\"1482153492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITL\" target=\"_blank\">MITL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231350-mitelplus-5-on-sale-of-mobile-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mitel +5% on sale of mobile business</a></h4><ul>\n<li>Mitel (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MITL\" title=\"Mitel Networks Corporation\">MITL</a>) agrees to sell its mobile division to Xura (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MESG\" title=\"Xura, Inc.\">MESG</a>) for $350M in cash, a $35M promissory note, and an equity interest in the entity that owns both Xura and the mobile division.</li>\n<li>The sale is the result of Mitel's annual business review in which the decision was made to refocus the company exclusively on the Unified Communications and Collaboration market.</li>\n<li>The deal is expected to close in Q1. Cash will be sued to pay down debt, cutting the gross leverage ratio to 1.8x from 3.3x. Mitel also expects to book a significant write-down of goodwill in Q4.</li>\n<li>A <a href=\"http://www.mitel.com\" target=\"_blank\">conference call </a>is set for 8:30 ET.</li>\n<li>Shares <font color=\"green\">+4.9%</font> premarket</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231350\" data-linked=\"Mitel +5% on sale of mobile business\" data-tweet=\"$MITL $MITL $MESG - Mitel +5% on sale of mobile business https://seekingalpha.com/news/3231350-mitelplus-5-on-sale-of-mobile-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3231350-mitelplus-5-on-sale-of-mobile-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":55,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}